Strongbridge Biopharma PLC (SBBP)
SBBP Stock Price Chart
Key Info
| Market Cap | 188.28M |
| Revenue (ttm) | 28.11M |
| Net Income (ttm) | -42.11M |
| Shares Out | 56.11M |
| EPS (ttm) | -0.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $2.80 |
| Previous Close | $2.74 |
| Change ($) | 0.06 |
| Change (%) | 2.19% |
| Day's Open | 2.76 |
| Day's Range | 2.73 - 2.82 |
| Day's Volume | 322,694 |
| 52-Week Range | 1.57 - 4.40 |
SBBP Stock News
~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing's Syndrome ~ ~ RECORLEV™ (levoketocon...
The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some p...
DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development an...
Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 11.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead fo...
~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGI...
DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development a...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP).
After reporting positive Recorlev Phase 3 top line data, SBBP management demonstrated incredible confidence by guiding investors to expect $250MM-$350MM/year in peak Recorlev sales/year.
~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndr...
~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Res...
Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows. If the data does not look good, SBBP options are very limited.
Strongbridge Biopharma plc's (SBBP) CEO John Johnson on Q2 2020 Results - Earnings Call Transcript
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 40.00% and 27.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...
~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~
DUBLIN, Ireland and TREVOSE, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Ireland and TREVOSE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...
Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020 Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020
DUBLIN, Ireland and TREVOSE, Pa., May 20, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development ...
Strongbridge Biopharma Attractive Valuation With Catalysts Approaching
Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020 Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020
Strongbridge Biopharma plc (SBBP) Management on Q1 2020 Results - Earnings Call Transcript
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 5.00% and 11.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...
Shares of Strongbridge Biopharma (NASDAQ:SBBP) were flat in pre-market trading after the company reported Q1 results.
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development ...
Strongbridge Biopharma plc (SBBP) Q4 2019 Results - Earnings Call Transcript
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 7.41% and 12.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...
DUBLIN, Ireland and TREVOSE, Pa., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...
Strongbridge Biopharma: A Big Opportunity For Cushing's Syndrome Patients And For Investors
~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2...
The fall in the stock price has created a compelling 'sum of the parts' valuation story and shares have stabilized recently.
~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of ...
Strongbridge Biopharma plc (SBBP) Q3 2019 Results - Earnings Call Transcript
DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Ireland and TREVOSE, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...
~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities and Characteristic Signs and Sympto...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...
Strongbridge Biopharma's (SBBP) CEO Matthew Pauls on Q2 2019 Results - Earnings Call Transcript
Strongbridge Biopharma has a promising clinical pipeline for the metabolic disease Cushing’s syndrome.
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 26.47% and -7.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for th...
Strongbridge Biopharma PLC (SBBP) CEO Matthew Pauls on Q1 2019 Results - Earnings Call Transcript
Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.
About SBBP
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotid... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2015 |
| CEO Matthew Pauls | Employees 71 |
| Stock Exchange NASDAQ | Ticker Symbol SBBP |
Analyst Forecasts
The average 12-month stock price forecast for SBBP is 7.80, which is an increase of 178.57% from the latest price.